Study Details

Back to Search Results

A Study to Assess ASP0598 Otic Solution Following Topical Application in the Ear in Subjects with Chronic Tympanic Membrane Perforation (CTMP)

Terminated/Withdrawn
The study has stopped early and will not start again. Participants were not enrolled (for withdrawn studies), however if participants were enrolled, they are no longer being examined or treated.

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT04305184

Astellas Study ID

The unique identification code given by the study sponsor.

0598-CL-0101

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

N/A

Follow Trial

Condition

Eardrum Perforation (Rupture)

Phase

These clinical trials are usually the first time an experimental treatment is studied in a small group of people.

Phase 1

Age

18 Years - 75 Years

Sex

Female & Male

Product

ASP0598

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Sep 2020 - Jan 2023

Masking

Double (Participant, Investigator)

Enrollment number

36

A Phase 1/2, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, Efficacy, and Pharmacokinetics of ASP0598 Otic Solution Following Topical application into the Ear in Subjects with Chronic Tympanic Membrane Perforation (CTMP)

Study summary

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A Study to Assess ASP0598 Otic Solution Following Topical Application in the Ear in Subjects with Chronic Tympanic Membrane Perforation (CTMP)? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Advanced ENT

Louisville, United States, 40220

Omaha ENT

Omaha, United States, 68118

Advanced ENT

New Albany, United States, 47150

Colorado ENT & Allergy

Colorado Springs, United States, 80909

University of Chicago

Chicago, United States, 60637

Columbia University Medical Center

New York, United States, 10032

University of Texas

Dallas, United States, 75235

Breathe Clear Institute

Torrance, United States, 90503

Piedmont ENT

Winston-Salem, United States, 27103

Ear Research Foundation

Sarasota, United States, 34329

Charlotte ENT Associates

Matthews, United States, 28105

ENT and Allergy Associates of Florida

Boca Raton, United States, 33487

Central California ENT

Fresno, United States, 93720

Richmond ENT

Richmond, United States, 23235

George Washington University

Washington, United States, 20037

Alamo ENT

San Antonio, United States, 78258

Carolina ENT Clinic

Orangeburg, United States, 29118

University of Arkansas

Little Rock, United States, 72205

University of Michigan

Ann Arbor, United States, 48109

Tufts Medical Center

Boston, United States, 02111

Stanford Hospital

Palo Alto, United States, 94304

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo